Literature DB >> 24970922

Cytokine profiles in polymyositis and dermatomyositis complicated by rapidly progressive or chronic interstitial lung disease.

Takahisa Gono1, Hirotaka Kaneko1, Yasushi Kawaguchi2, Masanori Hanaoka1, Sayuri Kataoka1, Masataka Kuwana1, Kae Takagi1, Hisae Ichida1, Yasuhiro Katsumata1, Yuko Ota1, Hidenaga Kawasumi1, Hisashi Yamanaka1.   

Abstract

OBJECTIVE: PM and DM are often complicated by interstitial lung disease (ILD). In this study we aimed to evaluate various serum cytokines in patients with PM/DM with ILD so as to clarify the differences in pathophysiology between anti-melanoma differentiation-associated gene 5 antibody-associated ILD (anti-MDA5-ILD) and anti-aminoacyl tRNA synthetase antibody-associated ILD (anti-ARS-ILD).
METHODS: We evaluated the serum cytokine profiles of 38 patients with PM/DM and compared the cytokine profiles of the non-ILD and ILD subsets as well as the anti-MDA5-ILD and anti-ARS-ILD subsets.
RESULTS: The myositis intention-to-treat activity index score, which indicates whole disease activity, significantly correlated with serum IL-6, IL-8, TNF-α and IP-10. These cytokine levels were significantly higher in the ILD subset than the non-ILD subset and were lower in the ILD subset following treatment. By multivariate analysis, TNF-α was the most significant cytokine [P = 0.0006, odds ratio (OR) 1.4, CI 1.1, 2.2] associated with PM/DM with ILD. IL-8 levels were significantly higher in anti-MDA5-ILD than in anti-ARS-ILD, although IL-6, TNF-α and IP-10 levels were high in both subsets. IL-8 was the most significant cytokine (P = 0.0006, OR 1.5, CI 1.1, 3.0) associated with anti-MDA5-ILD by multivariate analysis. Moreover, the ratio of IL-4 to IFN-γ was lower in anti-MDA5-ILD than in anti-ARS-ILD.
CONCLUSION: IL-6, IL-8, TNF-α and IP-10 are associated with global disease activity in PM/DM. These cytokine levels were high, especially in the ILD subset. Serum IL-8 levels and the balance between IL-4 and IFN-γ may contribute to the differences in pathophysiology between anti-ARS-ILD and anti-MDA5-ILD.
© The Author 2014. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For Permissions, please email: journals.permissions@oup.com.

Entities:  

Keywords:  IL-6; IL-8; TNF-α; dermatomyositis; interstitial lung disease; polymyositis

Mesh:

Substances:

Year:  2014        PMID: 24970922     DOI: 10.1093/rheumatology/keu258

Source DB:  PubMed          Journal:  Rheumatology (Oxford)        ISSN: 1462-0324            Impact factor:   7.580


  46 in total

Review 1.  Update on outcome assessment in myositis.

Authors:  Lisa G Rider; Rohit Aggarwal; Pedro M Machado; Jean-Yves Hogrel; Ann M Reed; Lisa Christopher-Stine; Nicolino Ruperto
Journal:  Nat Rev Rheumatol       Date:  2018-04-12       Impact factor: 20.543

2.  Incidence of autoimmune diseases in patients with scabies: a nationwide population-based study in Taiwan.

Authors:  Jui-Ming Liu; Feng-Hsiang Chiu; Chien-Yu Lin; Fung-Wei Chang; Ren-Jun Hsu
Journal:  Rheumatol Int       Date:  2017-04-18       Impact factor: 2.631

3.  Inflammatory myopathies: Choosing the right biomarkers to predict ILD in myositis.

Authors:  Takahisa Gono; Masataka Kuwana
Journal:  Nat Rev Rheumatol       Date:  2016-07-21       Impact factor: 20.543

Review 4.  The Immune Response and the Pathogenesis of Idiopathic Inflammatory Myositis: a Critical Review.

Authors:  Angela Ceribelli; Maria De Santis; Natasa Isailovic; M Eric Gershwin; Carlo Selmi
Journal:  Clin Rev Allergy Immunol       Date:  2017-02       Impact factor: 8.667

5.  Anti-MDA5 antibody-positive hypomyopathic dermatomyositis complicated with pneumomediastinum.

Authors:  Makiko Yashiro; Tomoyuki Asano; Shuzo Sato; Hiroko Kobayashi; Hiroshi Watanabe; Masayuki Miyata; Kiyoshi Migita
Journal:  Fukushima J Med Sci       Date:  2018

Review 6.  Selected aspects of the current management of myositis.

Authors:  James Lilleker; Sean Murphy; Robert Cooper
Journal:  Ther Adv Musculoskelet Dis       Date:  2016-06-19       Impact factor: 5.346

Review 7.  Immunological biomarkers in dermatomyositis.

Authors:  Jeannette M Olazagasti; Timothy B Niewold; Ann M Reed
Journal:  Curr Rheumatol Rep       Date:  2015-11       Impact factor: 4.592

8.  Serum IL8 and mRNA level of CD11b in circulating neutrophils are increased in clinically amyopathic dermatomyositis with active interstitial lung disease.

Authors:  Jing Zou; Jie Chen; Qingran Yan; Qiang Guo; Chunde Bao
Journal:  Clin Rheumatol       Date:  2015-10-12       Impact factor: 2.980

9.  ADAM-17 is expressed in the inflammatory myopathy and is involved with interstitial lung disease.

Authors:  Airi Nishimi; Takeo Isozaki; Shinichiro Nishimi; Sho Ishii; Takahiro Tokunaga; Hidekazu Furuya; Kuninobu Wakabayashi; Tsuyoshi Kasama
Journal:  Clin Rheumatol       Date:  2018-02-06       Impact factor: 2.980

Review 10.  Chemokines in rheumatic diseases: pathogenic role and therapeutic implications.

Authors:  Yoshishige Miyabe; Jeffrey Lian; Chie Miyabe; Andrew D Luster
Journal:  Nat Rev Rheumatol       Date:  2019-11-08       Impact factor: 20.543

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.